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Introduct ion  
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease with a preva- 
lence of 1.8-3% of the population [20]. In RA, the synovial tissue is invaded by in- 
flammatory cells. These leukocytes and their products play an essential role in synovi- 
tis, pannus formation and, eventually, joint destruction [20]. Cytokines are mediators 
involved in the inflammatory events underlying RA [15, 33]. The chemokine family 
consists of a number of distinct cytokines with structural homology. These proteins 
have potent chemotactic activity for cells of the immune system, and they appear to 
play a particularly important role in both the destructive and the fibrovasculoprolifer- 
ative phase of RA (reviewed in [34, 35, 45, 62, 65, 71]). Among cells present in the RA 
synovium, macrophages are a major source of chemokines [34, 35, 45]. Many of these 
chemokines are also involved in RA-associated angiogenesis, the formation of new 
blood vessels in the inflamed synovium (reviewed in [63]). 
Clinical management of RA is often difficult, and includes long-term use of im- 
munosuppressants. There are constant attempts to target specific points of the complex 
pathogenetic network underlying RA, including anti-cytokine therapy. 
Here we give a general introduction to chemokines (Table 1), followed by an 
overview of the most important chemokines that may play a role in RA. The chemo- 
kine interleukin (IL)-8 serves as prototype, since it has been studied most extensively 
in arthritis. We also discuss recent data on the possible role of certain chemokine re- 
ceptors in RA (Table 2). We then summarize the role of chemokines in context with 
other cytokines present in the RA synovium. Finally, we also give an overview on the 
clinical importance of chemokines by summarizing experimental data on anti-chemo- 
kine targeting in arthritis. 
Correspondence to: A. E. Koch 
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Table 1. Chemokine families and their most relevant representatives 
C-X-C chemokines 
Interleukin-8 (IL-8) a 
Epithelial-neutrophil activating protein-78 (ENA-78) a 
Growth-related gene product alpha (groc@ 
Growth-related gene product beta (gro[3) 
Granulocyte chemotactic protein-2 (GCP-2) 
Platelet basic protein 
Cormective tissue activating protein-III (CTAP-III) a 
NeutrophiI-activating protein-2 (NAP-2) 
[3-Thromboglobulin (~-TG) 
Interferon-7-inducible protein- 10 (IP- 10) 
Platelet factor 4 (PF4) 
Monokine induced by IFN- 7 (MIG) 
Stromal cell-derived factor (SDF-1) 
C-C chemokines 
Monocyte chemoattractant protein- l (MCP- 1)" 
Monocyte chemoattractant protein-2 (MCP-2) 
Monocyte chemoattractant protein-3 (MCP-3) 
Monocyte chemoattractant protein-4 (MCP-4) 
Macrophage inflammatory protein- 1 c~ (MIP- 1 (z) a 
Macrophage inflammatory protein- 1 [3 (MIP- 1 [3) 
Regulated upon activation normally T cell expressed and secreted (RANTES) ~ 
Eotaxin 
Thymus and activation-regulated chemokine (TARC) 
Liver and activation-regulated chemokine (LARC) 
Pulmonary and activation-regulated chemokine (PARC) 
Macrophage-derived chemokine (MDC) 
Human CC chemokine-1 (HCC-1) 
Human CC chemokine-2 (HCC-2) 
1-309 
Myeloid progenitor inhibitory factor 1 (MPIF-1) 
Myeloid progenitor inhibitory factor 2 (MPIF-2) 
EBI-1 ligand chemokine (ELC) 




a Chemokines of great importance in rheumatoid arthritis 
The subfamilies of chemokines 
Leukocy te  chemotax i s  and migra t ion  through the endothel ia l  barrier into the in f lamed 
synov ium is crucial  for the ini t iat ion and main tenance  o f  arthritis [20, 35]. The  identi-  
f icat ion of  chemotac t ic  cytokines,  t e rmed chemokines ,  led to the better  unders tanding 
of  this process.  M o n o m e r i c  chemokines  have  a molecu la r  mass of  less than 10 ki lo-  
daltons [45, 65, 71]. 
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Table 2. Chemokine receptors and their ligands a 
Chemokine receptor Ligand 
C-X-C chemokine receptors 
CXCR 1 
CXCR 2 b 
CXCR 3 
CXCR 4 (fusin) 
DARC (Duffy antigen receptor for chemokines) 











IL-8, ENA-78, gro, NAP-2 
IP-10, MIG 
SDF- 1 
IL-8, ENA-78, gro, NAP-2 
MCP-2, MCP-3, MIP-lc¢, RANTES, HCC-2 
MCP-1, MCP-2, MCP-3, MCP-4 
MCP-3, MCP-4, Eotaxin, RANTES, HCC-2 
TARC 




MCP-I, MIP-I ~ 
a See Table 1 for abbreviations 
b Major receptor for the angiogenic ELR-containing chemokines 
In the original description of  these chemotactic mediators, chemokines have been 
classified into two distinct supergene families based on their structural homology re- 
garding the location of two of  four conserved cysteine residues. In C-X-C chemokines, 
also known as tx chemokines,  these two conserved cysteines are separated by one un- 
conserved amino acid and hence the designation "C-X-C" (reviewed in [71]). In con- 
trast, the C-C chemokine (~ chemokine) subfamily members have adjacent conserved 
cysteine residues (reviewed in [65]). Both subfamilies include a number of mediators; 
however, only some of  these have been shown to play a role in the pathogenesis of in- 
f lammatory arthritis. 
Recently two additional chemokine families termed C chemokines and C-X-C3 
chemokines have been described based on the unique position of  cysteine residues [2, 
40]. The former family contains only one member  termed tymphotactin [40], while the 
C-X-C3 family consists of members expressed on cytokine-activated endothelia, but, 
in contrast to C-X-C and C-C chemokines,  not on peripheral  blood leukocytes [2]. We 
have not found any information on these new chemokine families in association with 
arthritis. 
C-X-C (ix) chemokines 
This chemokine subfamily includes, among many others, IL-8, epithelial-neutrophil 
activating protein (ENA)-78, growth-regulated oncogene o~ (groo0 and ~ (gro~), con- 
nective tissue activating peptide (CTAP)-III,  platelet factor-4 (PF4), and interferon- T- 
inducible protein (IP-10) (reviewed in [71]) (Table 1). C-X-C chemokines are mostly 
neutrophil chemotactic factors, although PF4 and IP-10 may also chemoattract mono- 
cytes and T lymphocytes [71]. 
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Table 3. Pro-angiogenic and anti-angiogenic C-X-C 
chemokines 
Pro-angiogenic Anti-angiogenic 





C-X-C chemokines mediate a number of mechanisms underlying inflammation. 
For example, IL-8 stimulates neutrophil chemotaxis and haptotaxis, 132 integrin ex- 
pression on, and L-selectin shedding from, leukocytes, adhesion to extracellular matrix 
components, cytoskeleton reorganization and actin polymerization, neutrophil degran- 
ulation, matrix metalloproteinase production, the release of leukotrienes and platelet- 
activating factor, the respiratory burst and phagocytosis (reviewed in [71 ]). 
Some C-X-C chemokines promote, while others inhibit angiogenesis [62, 63] 
(Table 3). It has been suggested recently that the ELR (glutamyl-leucyl-arginyl) motif 
found in a number of C-X-C chemokines, such as IL-8, ENA-78, gro~ and CTAP-III, 
is responsible for the angiogenic activity of these chemokines [62, 63]. In contrast, 
C-X-C chemokines lacking the ELR motif, such as PF4 and IP-10 are potent angiosta- 
tic mediators [62, 63]. Endothelial cells express receptors for angiogenic chemokines, 
such as IL-8, which is important for the initiation and maintenance of chemokine-me- 
diated neovascularization [55, 59]. 
C-C (~) chemokines 
The C-C chemokine subfamily consists of at least 20 members. The most relevant 
C-C chemokines for RA are monocyte chemoattractant protein (MCP)-I, macrophage 
inflammatory proteins (MIP)-1 c~ and -1 ~, as well as the chemokine termed Regulated 
upon Activation Normally T cell Expressed and Secreted (RANTES) (Table 1). These 
chemokines are essentially monocyte chemoattractants, but they may also be chemo- 
tactic for T cells, NK cells, basophils and eosinophils (reviewed in [65]). 
C-X-C chemokines in RA 
We and others have shown that among C-X-C chemokines described above, IL-8, 
ENA-78, groc~, and CTAP-III likely play a role in the pathogenesis of RA. IP-10, PF4 
and possibly gro~ seem to be less important in RA [21, 43, 75]. 
IL-8 
Detection of lL-8 in RA 
IL-8, a C-X-C chemokine (Table 1), has been detected in the synovial fluids, synovial 
tissues and, unlike a number of other cytokines, in the sera of RA patients [26, 60]. 
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Fig. 1. IL-8 expression in rheuma- 
toid synovial macrophages. (Im- 
munoperoxidase histochemistry: 
x 330) 
Several investigators, including our group, found increased levels of IL-8 in RA syno- 
vial fluids in comparison to other rheumatic diseases, such as osteoarthritis (OA) or 
gonococcal arthritis [11, 21, 26, 46, 49, 60]. RA synovial fluid IL-8 levels were gener- 
ally in the range of 1-18 ng/ml. Apart from the presence of antigenic IL-8 in these RA 
synovial fluid samples, we demonstrated that this IL-8 was bioactive. Immunoneutral- 
ization of IL-8 resulted in a significant down-regulation of RA synovial fluid-mediated 
neutrophil chemotactic activity in vitro [26]. 
IL-8 was also detectable in the sera of RA patients. Moreover, serum IL-8 levels 
showed significant positive correlation with IL-8 concentrations in synovial fluids 
[26]. Thus, measuring serum IL-8 may reflect intra-articular IL-8 levels, and it may 
serve as a useful tool in monitoring the escalation of inflammation within the joint. 
In RA synovial tissues, a number of cell types appear to produce IL-8 in situ (Fig. 1). 
Using immunohistochemistry, we found immunoreactive IL-8 in interstitial macro- 
phages, as well as in the synovial lining layer, which also contains macrophage-de- 
rived cells [26]. Others found a similar expression pattern with an additional endothe- 
lial reactivity [9]. These results suggest that the macrophage is among the principal 
producers of IL-8 in the synovial tissue. 
Producers of IL-8 in the RA synovium 
We have shown that isolated synovial macrophages produce abundant IL-8 mRNA and 
protein in vitro [26]. These cells, unlike synovial tissue fibroblasts, constitutively se- 
crete IL-8. As additional stimuli such as IL-1 cannot further increase IL-8 production, 
it is likely that macrophages are maximally stimulated in vivo to produce IL-8. Freshly 
isolated RA synovial fluid mononuclear cells synthesize more IL-8 mRNA and protein 
than do cells derived from the peripheral blood of the same patients [22]. 
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In contrast to macrophages, synovial fibroblasts produce IL-8 in vitro in the pres- 
ence of agonists including IL-lc~, IL-I~3, tumor necrosis factor (TNF)-o~ and 
lipopolysaccharide (LPS) [3, 22, 52]. IL-I~ and TNF-cz act synergistically in the stim- 
ulation of IL-8 secretion by RA synovial fibroblasts [52]. IL-1 and TNF-c~ may act by 
different mechanisms; as inhibition of protein synthesis resulted in superinduction of 
IL-8 mRNA in IL-1, but not TNF-o~-stimulated fibroblasts [3]. Furthermore, IL-4 fur- 
ther enhanced, while interferon- 7 inhibited both IL-1- and TNF-~-mediated IL-8 syn- 
thesis [51]. These data suggest that, unlike macrophages, synovial fibroblasts require 
exogenous stimulation to produce IL-8. 
Cartilage explants, as well as isolated chondrocytes are also capable of releasing 
IL-8 in vitro upon exposure to IL-1 [39, 53]. In addition, IL-8 synthesis by these cells 
requires the continuous presence of IL-1 [53]. 
In contrast to many other cytokines, including IL-1, -2, -3, -4, -7, granulocyte- 
macrophage (GM-CSF) and granulocyte colony-stimulating factors (G-CSF) or TNF-ot 
and -~3, IL-8 is increased in bone marrow aspirates from RA patients in comparison 
with normal subjects [64]. Moreover, IL-8 production by bone marrow cells correlated 
with the degree of synovitis in these patients. 
Functional aspects of lL-8 in RA 
Early investigations showed that human synovial cells stimulated with IL-1 in vitro re- 
leased a then-unknown low molecular weight factor, which stimulated neutrophil lo- 
comotion [72, 73]. It is likely that these investigators noted the effects of IL-8 or one 
of the related chemokines. 
IL-8 induces synovial inflammation, as determined by a single intra-articular in- 
jection of recombinant IL-8 into the rabbit knee joint [ 11]. Arthritis indicated by joint 
erythema and limp after 4 h post injection was associated with an early entry of neu- 
trophils into the synovial fluid, followed by the accumulation of mononuclear cells 8 h 
after injection. In the synovial tissue, neutrophil infiltration of the synovial lining and 
the perivascular area observed at 4 h post IL-8 injection was followed by the prolifer- 
ation of synovial lining cells and the thickening of the lining layer at 24 h post IL-8 in- 
jection. This multilayered lining layer was composed of macrophages and fibroblasts, 
and this histological picture was reminiscent of the human RA synovium. This study 
indicates that, in principal, IL-8 can induce joint inflammation and synovial changes 
similar to those found in RA patients. 
The onset and development of arthritis can also be studied by chemokine cDNA 
transfer to animal models of RA. Studies employing IL-8 gene transfer are still in early 
phases of development. Rabbit IL-8 cDNA can be transduced into rabbit synoviocytes 
using replication defective adenovirus [7]. This technique may help to study the effects 
of local and prolonged expression of IL-8 in an experimental model of arthritis. 
IL-8 may regulate adhesion molecule expression on leukocytes in RA. Synovial 
fluid IL-8 levels have been correlated with ~2 integrin expression on synovial fluid 
neutrophils in RA patients [8]. 
We have described a novel function for IL-8 as a mediator of angiogenesis [28] 
(Table 3). IL-8 is both chemotactic and mitogenic for endothelial cells in vitro and it is 
a potent angiogenic factor in in vivo models for angiogenesis. As anti-IL-8 antibody 
and IL-8 antisense oligonucleotides inhibited angiogenesis induced by peripheral 
blood monocytes and synovial tissue macrophages, IL-8 accounts for a significant por- 
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tion of monocyte/macrophage-derived angiogenic activity. As described above, IL-8 
contains the ELR motif, which may be responsible for its angiogenic effects found 
by us and other investigators [62, 63, 71]. Endothelial cells express receptors for IL-8 
[55, 59]. Thus, IL-8 is an important chemotactic cytokine which not only partici- 
pates in the inflammatory events, but also in new vessel formation underlying the 
parthogenesis of RA. 
ENA-78 
ENA-78 is a member of the C-X-C chemokine family. ENA-78 is a potent chemotactic 
factor for neutrophils and promotes neovascularization [63, 70, 71] (Tables 1 and 3). 
We have detected increased levels of ENA-78 in RA in comparison to OA synovial 
fluids [30]. Both RA synovial fluid mononuclear cells and synovial tissue fibroblasts 
produce ENA-78. ENA-78 synthesis by fibroblasts is augmented by TNF-ct pre-treat- 
ment. Within the synovial tissue, the main cellular source of this chemokine was the 
synovial lining cell layer, followed by interstitial macrophages, endothelial cells and 
fibroblasts. We found increased amounts of antigenic ENA-78 in the synovial tissues 
and sera from RA patients compared to normal subjects. Thus, for diagnostic purposes, 
ENA-78 can be readily measured in serum samples. ENA-78 is a very abundant pro- 
tein, with mean levels being approximately 15 times higher than mean IL-8 levels in 
RA synovial fluids. Thus, like IL-8, a major role of ENA-78 in RA appears to be the 
recruitment of neutrophils. 
We have recently studied the temporal expression of ENA-78 in the sera and joint 
homogenates of rats with adjuvant-induced arthritis, an animal model for RA (Hallo- 
ran et al., submitted). Arthritis was induced by a single injection of Mycobacterium bu- 
tyricurn and Freund's adjuvant. Almost all animals developed arthritis by day 14 post- 
adjuvant injection. Using an ELISA assay, we found significantly increased levels of 
antigenic ENA-78 in the sera of arthritic rats in comparison to sham-injected controls. 
This difference was first seen at day 7 post-adjuvant injection and serum levels of this 
chemokine continued to increase as arthritis developed. ENA-78 levels in ankle joint 
homogenates were increased in arthritic rats later in the development of the disease by 
day 18 post-adjuvant injection, compared to control rats. Expression of ENA-78 in 
both the sera and joint homogenates correlated with the progression of joint inflam- 
mation in arthritic animals. Thus, the increase in ENA-78 production in the sera and 
joints of rats may be important in the development of arthritis. 
Groo~ and gro[3 
Growth-related gene products (gro) c~ and ]3 are also members of the C-X-C 
chemokine subfamily [63, 71]. Both proteins stimulate the growth of fibroblasts, 
chemoattract neutrophils and stimulate angiogenesis [63, 71] (Tables 1 and 3). Grocz 
may also be involved in repair of the damaged joint, as this chemokine perpetuates col- 
lagen loss by inhibiting RA synovial fibroblast collagen production [67]. 
Regarding gro~z production in RA, we and others have found that synovial fluid 
neutrophils and mononuclear cells, isolated synovial tissue fibroblasts and articular 
chondrocytes produce gro(z mRNA and protein [3, 17, 22, 32, 53]. The synthesis of 
groc~ by RA synovial tissue fibroblasts could be stimulated by IL-lcz, IL-I[3 or TNF-cz. 
122 z. Szekanecz et al. 
Gro(z production by RA synovial fluid mononucler cells was further increased upon 
cell activation with LPS or phytohemagglutinin [22, 32]. Others reported an increased 
gro mRNA expression in RA synovial fluid mononuclear cells in comparison to 
mononuclear cells in peripheral blood from the same patients as well as from normal 
subjects [22]. 
We detected significantly increased synovial fluid concentrations of gro(z in RA in 
comparison to OA or other forms of arthritis. In addition, the serum level of this 
chemokine was also higher in RA patients than in normal subjects. In the synovial tis- 
sue, lining cells expressed more groc~ in RA than in OA patients or normal individuals. 
There was an increased expression of this chemokine in RA in comparison to OA sub- 
synovial macrophages [32]. 
One group recently examined the synovial production of gro(z and gro~ [21]. Cu- 
riously, these authors found that the majority of synovial fibroblast lines derived from 
OA or other non-inflammatory synovia showed a relative increase in the constitutive 
expression of groc~ and grog when compared to fibroblasts from RA synovia. More- 
over, these authors, in contrast to the findings of many other investigators, were also 
unable to detect IL-8 in any synovial fibroblast lines they examined by polymerase 
chain reaction, even upon stimulation with IL-1 or TNF-c~. It remains unclear whether 
the discordant results are due to technical differences between studies. It is still possi- 
ble that gro(z and gro[3 are produced in different quantities and may play a differential 
role in RA. 
Comparison of the relative role of IL-8, ENA-78 and gro(z in RA 
Since synovial fluids from RA patients have been shown to produce significant 
amounts of immunoreactive and bioactive IL-8, ENA-78 and gro(z, it may be impor- 
tant to know which of these chemokines plays the greatest role in leukocyte emigration 
into the joint. We simultaneously immunodepleted RA synovial fluids of IL-8, ENA- 
78 and gro(z, and measured the chemotactic response of normal neutrophils to these 
synovial fluids [32]. In our study, IL-8, ENA-78 and gro(z accounted for 36%, 34% 
and 28% of the chemotactic activity, respectively. These results suggest that all three 
chemokines are important in neutrophil recruitment into the RA joint, with IL-8 ac- 
counting for slightly more of the neutrophil chemotactic activity than the other two 
chemokines. Certainly, other functional studies are needed to determine the relative 
importance of these and other chemokines in various pathogenic mechanisms in 
RA. 
CTAP-III 
CTAP-III is a human platelet (z-granule-derived growth factor, which is more than 
100-times as abundant as other growth factors in plasma [6]. CTAP-III, as well as ~- 
thromboglobulin (~3TG) and neutrophil-activating protein (NAP)-2 are NH2-truncated 
cleavage products of platelet basic protein [63, 71]. CTAP-III stimulates endothelial 
chemotaxis and it is involved in angiogenesis [62, 63] (Tables 1 and 3). CTAP-III af- 
fects many aspects of connective tissue metabolism including the stimulation of DNA, 
hyaluronic acid, sulfated glycosaminoglycan chain, proteoglycan monomer, and pro- 
teoglycan core protein synthesis in human synovial fibroblast cultures [5, 6]. 
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Plasma of RA patients contains elevated level of CTAP-III but not 13TG or NAP-2 
[6]. This chemokine was also detected in RA and OA synovial tissue extracts [5]. 
IP-10 and PF4 
These C-X-C chemokines, unlike others described above, chemoattract monocytes and 
T cells rather than neutrophils [34, 71]. IP-10 and PF4 do not contain the ELR domain 
in their structure and have been shown to inhibit neovascularization [62, 63]. 
Very little IP-10 has been detected in the sera of RA patients [43]. A peptide se- 
quence from PF4 inhibited murine type II collagen-induced arthritis, a representative 
model for RA [75]. Thus, these two mediators, in contrast to other C-X-C chemokines 
discussed above, may be suppressors of arthritis-associated inflammatory and angio- 
genic mechanisms. 
C-C chemokines in RA 
MCP-1 
MCP-1 chemoattracts monocytes, T cells, NK cells and basophils [65]. Although there 
is little evidence for the role of MCP-1 in angiogenesis, MCP-1 mRNA expression is 
increased in growing hemangiomas and vascular malformations [23]. 
We and others have shown elevated levels of MCP-1 in synovial fluids from RA 
compared to OA patients [1, 27]. RA synovial fibroblasts produce MCP-1 in response 
to IL-lcz, IL-I[~, TNF-c~ or interferon- T, while articular chondrocytes secrete MCP-1 
upon stimulation by IL-113, TNF-c~ or transforming growth factor (TGF)-13 [19, 22, 68, 
69]. Mononuclear cells freshly isolated from RA synovial fluids produced more MCP- 
1 than cells from the peripheral blood of the same patients [22]. In the RA synovial tis- 
sue, interstitial macrophages are the major source of MCP-1 [27]. 
The main function of MCP-I in the joint may be the recruitment of macrophages, 
since injection of MCP-1 into rabbit joints resulted in marked infiltration of macro- 
phages into the synovial tissue [1]. 
MIP- 1 c~ and MIP- 113 
MIP-1 is a term applied originally to LPS-stimulated murine macrophage conditioned 
medium containing two distinct molecules, MIP-I~x and MIP-113, that copurified [74]. 
The human equivalents for these chemokines have recently been characterized [57, 
65]. Murine MIP-lc~ and 13 have 60% peptide identity and are 70% homologous to 
their human counterparts [74]. Despite their structural homology, their function in in- 
flammation including arthritis appears to be rather different. 
MIP-lc~ is chemotactic for monocytes, T, B and NK cells, basophils and 
eosinophils [65, 66]. In mice, MIP-lc~, but not MIP-1[3 stimulates the secretion of IL- 
113, TNF-o~ or IL-6 by macrophages [14, 41]. 
We found increased levels of MIP-lc~ in RA in comparison to OA synovial fluids 
[29]. Synovial fluid MIP-lc~ was bioactive and accounted for about 36% of synovial 
fluid-derived chemotactic activity for monocytes. We and others reported that synovial 
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fluid mononuclear cells and synovial tissue flbroblasts produce MIP-lo~ mRNA and 
protein [22, 29]. The production of this chemokine by fibroblasts could be further 
stimulated by IL-lc~ and TNF-o~. Like MCP-1, the main producers of MIP-lc~ in RA 
synovial tissue are macrophages and fibroblasts. Thus, MIP-lc~ appears to be a major 
factor facilitating the accumulation of macrophages in the RA joint. 
MIP-I~3 is a monocyte, T and NK cell chemoattractant [65]. Interestingly, in con- 
trast to many other chemokines we have examined, MIP-1 [3 concentration was signif- 
icantly increased in synovial fluids from patients with OA in comparison to RA [31]. 
There is relatively little MIP-1 ~ protein in RA synovial fluids [31], although others de- 
tected MIP-1 [3 mRNA in T cells isolated from RA peripheral blood or synovial fluid 
[54]. In our hands, this chemokine accounted for 28% of synovial fluid-induced 
chemotactic activity for monocytes in OA. Fibroblasts derived from OA synovial tis- 
sues did not constitutively produce MIP- 113. However, TNF-c~, IL- 113 or LPS treatment 
of these cells resulted in MIP-I~3 synthesis. In the OA synovial tissue, synovial lining 
cells, vascular endothelium, smooth muscle cells and a minority of macrophages ex- 
pressed MIP-I[3 [31]. Thus, MIP-I~ appears to be a chemokine, which, in contrast to 
most other chemokines, may play a role in leukocyte recruitment into the OA, rather 
than RA joint. 
RANTES 
RANTES is a chemotactic factor for monocytes, memory T lymphocytes, NK cells, 
eosinophils and basophils [58, 65]. RA synovial fibroblasts produce RANTES mRNA 
upon stimulation by TNF-c~, IL- 1 c~ or IL- 1 [3 [22, 51 ]. These effects of TNF-c~ or IL- 1 
on RANTES mRNA expression can be further increased by interferon-y, but down- 
regulated by IL-4 [51]. RANTES mRNA has also been detected in RA peripheral 
blood and synovial fluid T cells, as well as in sites of extensive lymphocytic infiltra- 
tion in RA synovial tissues [54]. 
Chemokine receptors in RA 
There are a number of known receptors for C-X-C and C-C chemokines abbreviated as 
"CXCR" and "CCR", respectively. These receptors exhibit a nonspecific affinity for 
their chemokine ligands (Table 2). It has been suggested recently that these chemokine 
receptors may play a different role in various inflammatory reactions. For example, 
CCR3 is expressed by lymphocytes exhibiting the Th2, but not the Thl phenotype. It 
is known that lymphocytes expressing the Th2 phenotype are mostly involved in hu- 
moral immunity. Accordingly, CCR3 is highly expressed in allergic lymphocytic infil- 
trates. In contrast, CCR5 is present on most Thl,  but not on Th2-type lymphocytes. 
Thl-type cells play an important role in cellular immunity so it is not surprising that 
CCR5 has been detected in RA synovial fluids and tissues. CXCR3 is present on both 
Thl-  and Th2-type cells, and this chemokine receptor is expressed in both allergic and 
synovial infiltrates [38]. Both CCR5 and CXCR3 show preferential expression on 
memory T cells showing the CD45RO ÷ phenotype [48]. 
There is relatively few data available on the possible role of chemokine receptors 
in RA. Among CXCR, CXCR3, while among CCR, CCR5 show strong expression on 
RA synovial fluid T lymphocytes, as well as in T cell-rich areas of RA synovial tissues 
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[38, 48]. Among chemokines listed in Table 1, the main ligand for CXCR3 is IP-10, 
while that for CCR5 is MIP-1 c~, MIP-1 [~ and RANTES [48] (Table 2). 
Regarding the possible role of chemokine receptors in angiogenesis, a number of 
these receptors may be detected on endothelial cells, thus playing a role in chemokine- 
derived angiogenesis. The role of endothelial IL-8 receptors is discussed above [55, 
59]. There is a growing body of evidence that CXCR2 may be the most important en- 
dothelial receptor for ELR-containing angiogenic CXC chemokines: CXCR2 is a ma- 
jor receptor for these chemokines [59, 63, 71]. C-X-C chemokines, such as IL-8 and 
NAP-2, bind to endothelial cells [59]. 
Cytokine-chemokine interactions in the RA synovium 
A regulatory network of pro-inflammatory cytokines, such as TNF-~ and IL-I[3, and 
chemokines exists in the inflamed synovium of RA patients [15, 33, 34]. Both TNF-c~ 
and IL-1 ~3 are abundantly produced in the RA joint [15, 33]. Monocytes/macrophages 
in the RA synovial fluid or synovial tissue constitutively express most chemokines, in- 
cluding IL-8 [26], ENA-78 [29], gro~ [32], MCP-1 [27] and MIP-lc~ [29]. In contrast 
to mononuclear cells, resting synovial fibroblasts and articular chondrocytes produce 
only small amounts of chemokines. However, TNF-c~, IL-lc~ or IL-I[~ stimulate RA 
synovial fibroblasts to secrete IL-8 [3, 22, 52], ENA-78 [30], groc~ [22, 32], MCP-1 
[19, 22, 68, 69], MIP-lc~ [22, 29] and RANTES [22, 51]. Interferon-y further enhances 
cytokine-mediated MCP-1 [19, 69] or RANTES production [51]. TNF-c~, IL-I~ or 
TGF-[~ trigger MCP-1 synthesis in RA articular chondrocytes [68]. We have described 
similar interactions between cytokines and MIP-1 [~ in the OA synovium [31 ]. As eval- 
uated using various protein kinase C inhibitors, this enzyme is involved in cytokine-in- 
duced IL-8, MCP-1 and RANTES synthesis by cultured human synovial fibroblasts 
[24]. 
The synovial microenvironment containing a mixture of various regulatory cy- 
tokines may influence the production of C-X-C and C-C chemokines and, thus, the 
outcome of synovial inflammation. Interestingly, TNF-~- or IL-1 ~3-mediated IL-8 syn- 
thesis by RA synovial fibroblasts is up-regulated by IL-4 but inhibited by interferon-y. 
In contrast, cytokine-dependent RANTES production by the same cells is decreased by 
IL-4 but stimulated by interferon-y [51]. Interferon-y is mostly produced by Thl-type 
lymphocytes, while IL-4 is secreted by Th2 cells. The major differences between Thl 
and Th2 cells are discussed above. These data suggest that the type of cellular infil- 
trate, namely the dominance of Thl or Th2 type lymphocytes, as well as their charac- 
teristic cytokine production, may result in a differential local chemokine pattern. 
There is also an inverse relationship between MIP-I~ and cytokines, at least in the 
case of murine macrophages [14, 41]. MIP-lc~ stimulates the synthesis of IL-lc~, TNF- 
c~ or IL-6 in these cells, suggesting a positive feedback mechanism between MIP- la  
and these cytokines. 
These two-way interactions may be important for the perpetuation of inflammatory 
mediator production within the inflamed synovium. In addition, not only direct 
chemokine targeting, but also suppressing the production of pro-inflammatory cy- 
tokines may be useful for controlling chemokine-mediated leukocyte ingress into the 
RA joint. 
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Clinical significance of chemokine studies in RA 
Relationship between chemokine production and clinical markers 
of disease activity in RA 
Measuring chemokine production in the sera of RA patients may be useful for moni- 
toring the disease course. Again, most investigations in this regard have been carried 
out on IL-8. 
It is difficult to find a consistent correlation between synovial fluid IL-8 levels and 
disease activity in RA. One group found a direct correlation between RA synovial fluid 
IL-8 concentration and joint leukocyte numbers or plasma C reactive protein levels 
[46]. Others were unable to correlate synovial fluid IL-8 levels and disease markers, 
such as synovial fluid leukocyte counts, erythrocyte sedimentation rate or C reactive 
protein levels [4, 49]. This controversy may be due to several factors, including the 
small number of patients examined in most studies or the insensitivity of most con- 
ventional disease markers. 
In another study, the possible role of IL-8 as an autoantigen in RA was suggested 
[47]. These investigators detected anti-IL-8 autoantibodies in the sera of RA patients 
and anti-IL-8 concentrations also correlated with disease activity. Thus, serum anti-IL- 
8 may provide a useful diagnostic marker for disease activity in RA. 
Other C-X-C chemokines, such as ENA-78 [30], groc~ [32] or CTAP-III [6] could 
also be readily measured and found in increased quantities in the sera of RA patients 
in comparison to normal controls. Thus, measuring the serum level of these chemo- 
kines may also closely reflect the inflammatory processes underlying RA. 
Chemokine targeting strategies in RA 
Chemokine production in the RA joint can be influenced in a number of ways. Non- 
specific strategies include the use of anti-inflammatory drugs, which, apart from many 
other mechanisms of action, also affect chemokine production. Alternatively, as pro- 
inflammatory cytokines, mainly TNF-o~ and IL-I[~, stimulate the production of most 
chemokines by RA synovial fibroblasts or macrophages, the use of cytokine antago- 
nists, anti-cytokine antibodies or soluble cytokine receptors may also down-regulate 
chemokine synthesis. Most of these approaches have already been tried in RA. Finally, 
preliminary studies using antibodies to chemokines and chemokine inhibitors carried 
out in animal models of RA suggest that direct, specific chemokine targeting may also 
be available in the near future. 
Effects of anti-inflammatory agents on chemokines 
IL-8 production may be modulated by a number of immune modulators currently used 
in the therapy of RA or other inflammatory arthritides. Among the most potent sup- 
pressors of IL-8 production are corticosteroids. RA synovial fluid mononuclear cell 
production of IL-8 was inhibited by dexamethasone [60]. Dexamethasone also sup- 
pressed the production of IL-8 by RA synovial fibroblasts by 60-80% [37]. These au- 
thors also found that when RA patients were given intra-articular betamethasone, their 
synovial fluid mononuclear cells exhibited decreased spontaneous and LPS-dependent 
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release of IL-8. Suppressed IL-8 synthesis was accompanied by a significant decrease 
leukocyte and neutrophil counts. Pulse corticosteroid therapy suppressed synovial 
fluid IL-8 levels, as well as IL-8 expression in the synovial tissue lining layer in RA 
patients [76]. These results suggest that IL-8 production by a number of synovial cells 
may by modified clinically by anti-rheumatic drugs, such as corticosteroids. Gluco- 
corticoids bind to intracellular receptors that recognize glucocorticoid-responsive ele- 
ments in the promoter regions of genes. It may be that glucocorticoids act in this way 
to modulate chemokine gene expression. 
In contrast to the effects observed with corticosteroids, non-steroidal anti-inflam- 
matory drugs or disease modifying agents had little effect on IL-8 synthesis. For ex- 
ample, indomethacin treatment of RA synovial fluid mononuclear cells or synovial fi- 
broblasts did not decrease IL-8 synthesis in vitro [37, 60]. Other compounds such as 
piroxicam, naproxen, and tiaprofenic acid were also unable to inhibit IL-8 production 
by RA synovial fibroblasts. Sodium thiomalate inhibited RA synovial fibroblast IL-8 
production only in suboptimally stimulated cells in vitro [37]. Methotrexate was also 
found to be ineffective in suppressing IL-8 production by fibroblasts [37], although in 
a recent study it decreased IL-8 secretion by RA peripheral blood mononuclear cells in 
response to LPS [61]. 
Like IL-8, MCP-1 production can be altered by anti-rheumatic drugs and immune 
modulators. Dexamethasone and, to a much lesser extent, gold sodium thiomalate, in- 
hibited the production of MCP-1 by RA synovial fibroblasts [37]. Dexamethasone 
blunted the induction of MCP-1 expression by IL-1 in human articular chondrocytes 
[68]. Again, methotrexate and nonsteroidal anti-inflammatory compounds were inac- 
tive in reducing MCP-1 production by RA fibroblasts or mononuclear cells [37, 61]. 
These data suggest that part of the anti-rheumatic action of corticosteroids, but not 
that of nonsteroidal anti-inflammatory drugs or disease-modifying agents is due to the 
inhibition of IL-8 and MCP-1 production and, thus, the prevention of leukocyte accu- 
mulation in the inflamed joint. 
TNF-cz induces chemokine production in part via generation of reactive oxygen in- 
termediates. Antioxidants, such as N-acetyl-L-cysteine and 2-oxothiazolidine-4-car- 
boxylate, suppressed TNF-y-induced IL-8 and MCP-1 mRNA synthesis in isolated hu- 
man synovial cells [56]. These antioxidants may be useful in inhibiting chemokine 
production in RA. 
Specific inhibition of TNF-os and IL-l fl synthesis in the RA joint 
The suppression of pro-inflammatory cytokine production may also block the synthe- 
sis of cytokine-dependent chemokines. There are several ongoing studies using anti- 
cytokine monoclonal antibodies, soluble cytokine receptors, cytokine receptor antago- 
nists or gene therapy conducted in RA patients. As these anti-cytokine trials are dis- 
cussed elsewhere in this issue, we briefly mention the most relevant ones. Engineered 
anti-TNF-o~ monoclonal antibodies gave the best results (reviewed in [16, 50]), but re- 
combinant, soluble TNF-o¢ [42] and IL-1 receptors [10], as well as IL-1 receptor antag- 
onist protein (IL-lra or IRAP) [36] have been tried in refractory RA. Somatic gene tran- 
fer using a cDNA expression vector carrying human IL-lra cDNA has been developed 
and approved for use in RA patients not responding to conventional treatment [12, 13]. 
In summary, although we have not found any data directly showing the effects of 
any mentioned therapies on chemokine production, it is possible that by inhibiting the 
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effects of TNF-tx or IL-I[3 one may mitigate cytokine-induced chemokine secretion. 
Thus, efforts aimed at interrupting the cytokine network involving chemokine produc- 
tion may be beneficial in the therapy of RA. 
Direct chemokine targeting 
The inflammatory action of chemokines may be directly suppressed using specific an- 
tibodies or other inhibitors. As described above, in our hands, antibodies to IL-8, ENA- 
78 and grotx partially neutralized RA synovial fluid-derived chemotactic activity for 
neutrophils in vitro [32]. We have used neutralizing anti-ENA-78 antibody to treat rats 
with adjuvant-induced arthritis, a model for RA (Halloran et al., submitted). Anti- 
ENA-78 administered intravenously prior to the onset of arthritis attenuated the sever- 
ity of the disease as determined by joint circumference measurements. In addition, 
anti-ENA-78 significantly reduced the number of IL-l~3-immunoreactive cells in the 
synovial lining layer, indicating the possible role of ENA-78 in the maintenance of cy- 
tokine production in the synovium. This antibody was unable to influence the disease 
course when injected during the development of arthritis. These data suggest that anti- 
chemokine antibodies may inhibit the progression of arthritis. 
Other anti-chemokine antibodies have also been tried in arthritis models. Passive 
immunization with anti-MIP- 1 tx delayed the onset and reduced the severity of type II 
collagen-induced arthritis in mice [25, 35]. A neutralizing monoclonal antibody to 
MCP-1 reduced ankle swelling by 30% and significantly decreased the number of sy- 
novial macrophages in type II collagen-induced arthritis in rats [44]. 
Apart from antibodies, chemokine antagonists or angiostatic chemokines may also 
be used as anti-rheumatic agents. For example, a 67-amino acid sequence of MCP-1, 
which acts as an MCP-1 antagonist in vitro, abrogated arthritis in MRL-lpr autoim- 
mune mice [18]. A bioactive synthetic peptide derived from the angiogenesis inhibitor 
chemokine PF4 suppressed type II collagen-induced arthritis in mice [75]. 
Conclusions 
In this review we have discussed the putative role of chemokines in RA. A number of 
C-X-C and C-C chemokines are involved in the inflammatory and angiogenic events 
underlying the pathogenesis of arthritis. In addition, chemokine research has important 
clinical implications. For example, some of these mediators are detectable in the serum 
of RA patients and may eventually serve as useful laboratory markers of disease activ- 
ity. Moreover, chemokine overproduction detected in RA and other forms of inflam- 
matory arthritis may be therapeutically targeted with anti-inflammatory agents or cy- 
tokine inhibitors. In the next decade, it is likely that clinically available specific antag- 
onists of chemokines or their receptors will be developed. Future directions in cy- 
tokine and chemokine research may also include somatic gene therapy. 
Given the sometimes limited efficacy of currently used anti-rheumatic therapies, 
we must consider alternative strategies to treat RA patients. These approaches may in- 
clude the ablation of inflammatory mediators including chemokines. Hopefully, the 
study of chemokines and their interactions with other components of the inflammatory 
network present in the inflamed synovium will lead to the development of specific im- 
munomodulatory therapies that will prevent joint destruction and, thus, benefit RA pa- 
tients. 
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